Results 41 to 50 of about 65,110 (152)

Commentary on “Electroacupuncture Inhibited Spinal Glial Activation in Neuropathic Pain via Glucagon-like Peptide 1/Glucagon-like Peptide 1 Receptor Signaling”

Neurological Sciences and Neurophysiology
Neuropathic pain represents a significant clinical challenge due to its complex etiology and limited treatment options. Traditional pharmacological approaches, particularly opioid therapy, are associated with significant side effects and risk of abuse ...
Hulya Karatas
doaj   +1 more source

GLP-1 and Its Role in Glycogen Production: A Narrative Review

Biomedicines
Glucagon-like peptide-1 (GLP-1) has emerged as a pivotal regulator in the management of glucose homeostasis, glycogen metabolism, and energy balance, positioning it as a critical therapeutic target for addressing obesity, metabolic syndrome, and type 2 ...
Joseph Lotosky, Xavier Jean, Anungoo Altankhuyag, Saqib Khan, Ashley Bernotas, Alireza Sharafshah, Kenneth Blum, Alan Posner, Panayotis K. Thanos   +8 more
doaj   +1 more source

A real-world propensity analysis of the impact of GLP-1 receptor agonists on cancer therapy-related cardiac dysfunction

Communications Medicine
Background Heart damage caused by cancer treatment can lead to heart failure, hospital admission, and death. Medications known as glucagon-like peptide-1 receptor agonists are widely used to treat type 2 diabetes with cardioprotective potentials. Whether
Jheng-Yan Wu, Yu-Min Lin, Mei-Chuan Lee, Chung-Han Ho, Pei Yu Jhou, Wei-Ting Chang   +5 more
doaj   +1 more source

GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies

Pharmacological Research
The emergence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) represents a major breakthrough in the pharmacotherapy of obesity. However, their single-target mechanism has limitations.
Xinyao Wang, Rutao Lin, Qinmei Sun, Xin Xin, Qin Feng   +4 more
doaj   +1 more source

A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease

Therapeutics and Clinical Risk Management, 2022
Zeyu Xie, Jinjian Li, Sensen Yang, Weishang Deng, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Li J, Yang S, Deng W, Chen J
doaj  

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea

Obesity Science & Practice
Background and Aim Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are well‐established therapies for obesity and type 2 diabetes mellitus (T2DM). Emerging evidence also suggests their potential role in managing obstructive sleep apnea (OSA).
Bei‐Bei Qian, Yu‐Jie Huang, Cai‐Feng Yan, Shang‐Yong Feng, Dun‐Min She   +4 more
doaj   +1 more source

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias

Journal of Arrhythmia
Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity‐related cardiovascular risks.
Vikash Jaiswal, Muhammad Hanif, Aman Goyal, Juveriya Yasmeen, Vamsi Garimella, Yusra Mashkoor, Roopeessh Vempati, Novonil Deb, Yusra Minahil Nasir, Kripa Rajak, Abhigan Babu Shrestha, Jishanth Mattumpuram, Andrew Weinberg   +12 more
doaj   +1 more source

Physiology and pharmacology of glucagon-like peptide-1 receptor

Фармация и фармакология (Пятигорск)
Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks.
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, V. I. Petrov, A. V. Strygin, K. N. Koryanova, Yu. V. Gorbunova, Yu. A. Kolosov, O. V. Ivanova, E. V. Pavlova, M. A. Dzhavakhyan, A. V. Zaborovsky, V. B. Saparova, I. E. Makarenko, R. I. Drai, A. N. Chumachenko   +15 more
doaj   +1 more source

Unraveling the obesity–asthma link: A new horizon with glucagon-like peptide-1 receptor agonists in a complex intersection of metabolism and airway disease

Journal of International Medical Research
The global prevalence of obesity and asthma has escalated in parallel over recent decades, presenting an intertwined public health crisis. Obesity not only increases the risk of asthma development but also complicates its clinical course by altering ...
Francesco Menzella, Marcello Cottini, Rory Chan   +2 more
doaj   +1 more source

Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain

Neural Regeneration Research
The glucagon-like peptide 1 is a pleiotropic hormone that has potent insulinotropic effects and is key in treating metabolic diseases such as diabetes and obesity. Glucagon-like peptide 1 exerts its effects by activating a membrane receptor identified in
Yolanda Diz-Chaves, Zainab Maastor, Carlos Spuch, José Antonio Lamas, Lucas C González-Matías, Federico Mallo   +5 more
doaj   +1 more source